NOTCH1 and B-cell chronic lymphocytic leukemia: In the scenario where the majority of CLL patients respond to ibrutinib or venetoclax, NOTCH1-mutated patients still represent an aggressive subgroup of the disease, as NOTCH1 mutation showed to be an independent predictor of survival and Richter transformation [16,67,68].